Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Dow
Covington
Cipla
Harvard Business School
Moodys
Cantor Fitzgerald
Baxter
Chinese Patent Office
Boehringer Ingelheim

Generated: July 22, 2018

DrugPatentWatch Database Preview

Vincristine sulfate - Generic Drug Details

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

What are the generic sources for vincristine sulfate and what is the scope of vincristine sulfate patent protection?

Vincristine sulfate
is the generic ingredient in six branded drugs marketed by Talon Therap, Lilly, Teva Parenteral, Bristol Myers Squibb, Abic, Abraxis Pharm, Fresenius Kabi Usa, Hospira, and Teva Pharms Usa, and is included in thirteen NDAs. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Vincristine sulfate has forty-five patent family members in sixteen countries.

There are thirteen drug master file entries for vincristine sulfate. Three suppliers are listed for this compound.
Pharmacology for vincristine sulfate
Ingredient-typeVinca Alkaloids
Drug ClassVinca Alkaloid
Medical Subject Heading (MeSH) Categories for vincristine sulfate

US Patents and Regulatory Information for vincristine sulfate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teva Parenteral VINCASAR PFS vincristine sulfate INJECTABLE;INJECTION 071426-001 Jul 17, 1987 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Fresenius Kabi Usa VINCRISTINE SULFATE vincristine sulfate INJECTABLE;INJECTION 076401-001 Oct 28, 2003 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Talon Therap MARQIBO KIT vincristine sulfate INJECTABLE, LIPOSOMAL;INTRAVENOUS 202497-001 Aug 9, 2012 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Talon Therap MARQIBO KIT vincristine sulfate INJECTABLE, LIPOSOMAL;INTRAVENOUS 202497-001 Aug 9, 2012 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Expired US Patents for vincristine sulfate

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Talon Therap MARQIBO KIT vincristine sulfate INJECTABLE, LIPOSOMAL;INTRAVENOUS 202497-001 Aug 9, 2012 ➤ Try a Free Trial ➤ Try a Free Trial
Talon Therap MARQIBO KIT vincristine sulfate INJECTABLE, LIPOSOMAL;INTRAVENOUS 202497-001 Aug 9, 2012 ➤ Try a Free Trial ➤ Try a Free Trial
Talon Therap MARQIBO KIT vincristine sulfate INJECTABLE, LIPOSOMAL;INTRAVENOUS 202497-001 Aug 9, 2012 ➤ Try a Free Trial ➤ Try a Free Trial
Lilly ONCOVIN vincristine sulfate INJECTABLE;INJECTION 014103-003 Mar 7, 1984 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for vincristine sulfate

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,060,828 Liposomal camptothecins and uses thereof ➤ Try a Free Trial
7,244,448 Liposomal antineoplastic drugs and uses thereof ➤ Try a Free Trial
7,244,450 Compositions and methods for treating lymphoma ➤ Try a Free Trial
7,311,924 Compositions and methods for treating cancer ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Boehringer Ingelheim
Fish and Richardson
Queensland Health
Medtronic
Argus Health
Accenture
Baxter
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.